Long-Term Pioglitazone Effective for Nonalcoholic Steatohepatitis in Type 2 Diabetes

Share this content:
Researchers found that 51% of patients taking pioglitazone had NASH resolution.
Researchers found that 51% of patients taking pioglitazone had NASH resolution.

(HealthDay News) – For patients with prediabetes or type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis (NASH), long-term pioglitazone is safe and effective, according to a study published in the Annals of Internal Medicine.

Kenneth Cusi, MD, from the University of Florida and Malcom Randall Veterans Affairs Medical Center in Gainesville, and colleagues conducted a randomized trial involving 101 patients with prediabetes or T2DM and biopsy-proven NASH. Participants were prescribed a hypocaloric diet and randomized to pioglitazone or placebo for 18 months, followed by an 18-month open-label pioglitazone treatment phase.

 

The researchers found that 58% of patients randomized to pioglitazone achieved the primary outcome of a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score, without worsening of fibrosis, and 51% had NASH resolution (both P<.001). Pioglitazone treatment correlated with improved histologic scores; reduced hepatic triglyceride content; and improved adipose tissue, hepatic, and muscle insulin sensitivity (P<.001 vs placebo). Over 36 months of therapy, all 18-month metabolic and histologic improvements persisted.

"These results suggest that NASH progression may be halted and the natural history of the disease may be modified with the use of pioglitazone in patients with prediabetes or T2DM," the authors write.

One author disclosed financial ties to pharmaceutical companies, including Takeda, which provided the pioglitazone and placebo tablets for the study.

Reference

  1. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized, controlled trial. Ann Intern Med. 2016; doi:10.7326/M15-1774.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus